natgillin/translations-raw huggingface dataset:
A method according to claim 1 wherein the cement is a material obtained by intergrinding of clinker, gypsum and, optionally limestone, fly ash, pozzolan materials, rapid cooled blast furnace slag. 
Metoda prema patentnom zahtjevu 1 naznačeno time da cement jest materijal dobiven usitnjavanjem klinkera, gipsa, a može i vapnenca, lebdećeg pepela, pucolanskih materijala, brzo ohlađene troske od visokih peći.
A method according to claim 1 wherein the additive is added to cement during grinding, bagging or packaging. 
Metoda prema patentnom zahtjevu 1 naznačeno time da je aditiv dodan u cement tijekom usitnjavanja, smještanja u vreće ili pakiranja.
wherein z" may be present or absent, but if present is a capping moiety covalently attached at the 5'-terminus of (N')y; 
gdje z″ može biti prisutan ili odsutan, no ako je prisutan je ostatak koji vrši ulogu kape, kovalentno vezan na 5′-kraj (N′)y;
The pharmaceutical composition according to claim 1, wherein the drug carrier the comprises a stellate cell-specific amount of the polyethylene glycol molecule-conjugated retinoid molecule. The pharmaceutical composition of claim 1 or 2, wherein the double-stranded nucleic acid molecule comprises oligonucleotide sequences selected from the group consisting of the sequences SEQ ID NOS: 60 and 127 (SERPINH1_2) SEQ ID NOS: 98 and 165 (SERPrNH1_45a), and SEQ ID NOS: 101 and 168 (SERPINH1_51). 
dvolančanu molekulu nukleinske kiseline koja sadrži smisleni lanac i protusmisleni lanac, gdje se smisleni i protusmisleni lanac bira između oligonukleotida opisanih kao SERPINH1_2 (SEQ ID NO: 60 i 127), SERPINH1_45a (SEQ ID NO: 98 i 165) i SERPINH1_51 (SEQ ID NO: 101 i 168), te nosač lijekova, koji sadrži smjesu lipidne vezikule i retinoida ili retinoidnog konjugata, gdje lipid lipidne vezikule uključuje lipid kojeg se bira iz skupine koju čine i .
The pharmaceutical composition according to claim 10, wherein the antisense strand comprises SEQ ID NO:127, and the sense strand comprises SEQ ID NO:60. The pharmaceutical composition according to claim 11, wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides; a 2'-5'-ribonucleotide in at least one of positions 1, 5, 6, or 7; and a non-nucleotide moiety covalently attached to the 3'-terminus; and wherein the sense strand further comprises at least one 2'-5'-ribonucleotide or 2'-O-methyl modified ribonucleotide; a non-nucleotide moiety covalently attached at the 3'-terminus; and a cap moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide; 2′-5′-ribonukleotid na najmanje jednom od položaja 1, 5, 6, ili 7; i nenukleotidni ostatak kovalentno vezan na 3′-kraju; te gdje smisleni lanac dodatno sadrži najmanje jedan 2′-5′-ribonukleotid ili 2′-O-metilom modificirani ribonukleotid; nenukleotidni ostatak kovalentno vezan na 3′-kraju; i ostatak koji vrši ulogu kape kovalentno vezan na 5′-kraju.
The pharmaceutical composition according to claim 11, wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides at positions 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a non-nucleotide moiety covalently attached at the 3'-terminus; and wherein the sense strand further comprises five consecutive 2'-5'-ribonucleotides in the 3'-terminal positions 15, 16, 17, 18, and 19; a non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 3, 5, 9, 11, 13, 15, 17, te 19; 2′-5′-ribonukleotid na položaju 7; i nenukleotidni ostatak kovalentno vezan na 3′-kraju; te gdje smisleni lanac dodatno sadrži pet uzastopnih 2′-5′-ribonukleotida na 3′-terminalnim položajima 15, 16, 17, 18, te 19; nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni ostatak kovalentno vezan na 5′-kraju.
The pharmaceutical composition according to claim 11, wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, and 19; and a C3C3 non-nucleotide moiety covalently attached at the 3'-terminus; and wherein the sense strand further comprises a C3Pi non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 3, 5, 9, 11, 13, 15, 17, te 19; i C3C3 nenukleotidni ostatak kovalentno vezan na 3′-kraju; te gdje smisleni lanac dodatno sadrži C3Pi nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni ostatak kovalentno vezan na 5′-kraju.
The pharmaceutical composition according to claim 11, wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides at positions 1, 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and wherein the sense strand further comprises five consecutive 2'-5'-ribonucleotides in the 3'-terminal positions 15, 16, 17, 18, and 19; a C3Pi non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 3, 5, 9, 11, 13, 15, 17, te 19; 2′-5′-ribonukleotid na položaju 7; i C3Pi-C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju; te gdje smisleni lanac dodatno sadrži pet uzastopnih 2′-5′-ribonukleotida na 3′-terminalnim položajima 15, 16, 17, 18, te 19; C3Pi nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni ostatak kovalentno vezan na 5′-kraju.
The pharmaceutical composition according to claim 11, wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 1, 3, 5, 9, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi- C3OH non-nucleotide, moiety covalently attached at the 3'-terminus; and wherein the sense strand further comprises 2'-O-methyl modified ribonucleotides in positions 7, 13, 16 and 18; a 2'-5'-ribonucleotide at position 9; a C3 non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic moiety covalently attached at the 5'-terminus. The pharmaceutical composition according to any of claims 1-9, wherein one strand of the double-stranded nucleic acid molecule comprises SEQ ID NO:98 and the second strand comprises SEQ ID NO: 165. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što protusmisleni lanac sadrži SEQ ID NO:127, a smisleni lanac sadrži SEQ ID NO:60; gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 3, 5, 9, 11, 13, 15, 17, te 19; 2′-5′-ribonukleotid na položaju 7; i C3Pi-C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju; te gdje smisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 7, 13, 16 i 18; 2′-5′-ribonukleotid na položaju 9; C3 nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni ostatak kovalentno vezan na 5′-kraju.
The pharmaceutical composition according to claim 17, wherein the sense strand comprises SEQ ID NO:98 and the antisense strand comprises SEQ ID NO:165: The pharmaceutical composition according to claim 18, wherein the sense strand further comprises 2'-5'-ribonucleotides in positions at or near the 3'-terminus; a non-nucleotide moiety covalently attached at the 3'-terminus; and a cap moiety covalently attached at the 5'-terminus; and the antisense strand further comprises a 2'-O-methyl modified ribonucleotide; a 2'-5'-ribonucleotide in at least one of positions 5, 6 or 7; and a non-nucleotide moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2′-5′-ribonukleotide na položajima na ili blizu 3′-kraja; nenukleotidni ostatak kovalentno vezan na 3′-kraju; i ostatak koji vrši ulogu kape kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirani ribonukleotid; 2′-5′-ribonukleotid na najmanje jednom od položaja 5, 6 ili 7; i nenukleotidni ostatak kovalentno vezan na 3′-kraju.
The pharmaceutical composition according to claim 18, wherein the sense strand further comprises 2'-5'-ribonucleotides in positions 15, 16, 17, 18, and 19; a C3-OH 3' moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 2, 4, 6, 8, 11, 13, 15, 17, and 19; a 2'-5'-ribonucleotide in position 7; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. The pharmaceutical composition according to any of claims 1-9, wherein one strand of the double-stranded nucleic acid molecule comprises SEQ ID NO:101 and the second strand comprises SEQ ID NO:168. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2′-5′-ribonukleotide na položajima 15, 16, 17, 18, te 19; C3-OH 3′ ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 2, 4, 6, 8, 11, 13, 15, 17, te 19; 2′-5′-ribonukleotid na položaju 7; i C3Pi-C3OH ostatak kovalentno vezan na 3′-kraju.
The pharmaceutical composition according to claim 21, wherein the sense strand comprises SEQ ID NO:101 and the antisense strand comprises SEQ ID NO:168. The pharmaceutical composition according to claim 22, wherein the sense strand further comprises 2'-O-methyl modified pyrimidine ribonucleotides; an optional 2'-5'-ribonucleotide in one of position 9 or 10; a non-nucleotide moiety covalently attached at the 3'-terminus; and a cap moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises a 2'-O-methyl modified ribonucleotide; a 2'-5'-ribonucleotide in at least one of positions 5, 6, or 7; and a non-nucleotide moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2′-O-metilom modificirane pirimidinske ribonukleotide; izborni 2′-5′-ribonukleotid na jednom od položaja 9 ili 10; nenukleotidni ostatak kovalentno vezan na 3′-kraju; i ostatak koji vrši ulogu kape kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirani ribonukleotid; 2′-5′-ribonukleotid na najmanje jednom od položaja 5, 6, ili 7; i nenukleotidni ostatak kovalentno vezan na 3′-kraju.
The pharmaceutical composition according to claim 22, wherein the sense strand further comprises 2'-O-methyl modified ribonucleotides in positions 4, 11, 13, and 17; a 2'-5'-ribonucleotide in position 9; a C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 1, 4, 8, 11 and 15; a 2'-5'-ribonucleotide in position 6; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 4, 11, 13, i 17; 2′-5′-ribonukleotid na položaju 9; C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 4, 8, 11 i 15; 2′-5′-ribonukleotid na položaju 6; i C3Pi-C3OH ostatak kovalentno vezan na 3′-kraju.
The pharmaceutical composition according to claim 22, wherein the sense strand further comprises 2'-O-methyl modified ribonucleotides in positions 4, 11, 13, and 17; a C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 1, 4, 8, 13 and 15; a 2'-5'-ribonucleotide in position 6; and a C3Pi-C3OH moiety covalently attached at the 3'-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 4, 11, 13, i 17; C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 4, 8, 13 i 15; 2′-5′-ribonukleotid na položaju 6; i C3Pi-C3OH ostatak kovalentno vezan na 3′-kraju.
The pharmaceutical composition according to claim 22, wherein the sense strand further comprises 2'-O-methyl modified ribonucleotides in positions 2, 4, 11, 13, and 17; a C3OH non-nucleotide moiety covalently attached at the 3'-terminus; and an inverted abasic deoxyribonucleotide moiety covalently attached at the 5'-terminus; and wherein the antisense strand further comprises 2'-O-methyl modified ribonucleotides in positions 1, 4, 8, 11 and 15; a 2'-5'-ribonucleotide in position 6; and a C3Pi-C3OH non-nucleotide moiety covalently attached at the 3'-terminus. The pharmaceutical composition according to any of claims 1-26, which is parenterally administered. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:101, a protusmisleni lanac sadrži SEQ ID NO:168; gdje smisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 2, 4, 11, 13, i 17; C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju; i invertirani nebazni deoksiribonukleotidni ostatak kovalentno vezan na 5′-kraju; i gdje protusmisleni lanac dodatno sadrži 2′-O-metilom modificirane ribonukleotide na položajima 1, 4, 8, 11 i 15; 2′-5′-ribonukleotid na položaju 6; i C3Pi-C3OH nenukleotidni ostatak kovalentno vezan na 3′-kraju.
An aqueous ethyl alcohol free paediatric solution comprising propranolol or pharmaceutically acceptable salts thereof, a non sugar type sweetener and less than 0.01 w/V% of any preservative agents, other than propranolol itself, for use as a medicament in the treatment of hemangiomas. 
Vodena pedijatrijska otopina bez etilnog alkohola koji sadrži propranolol ili njegovu farmaceutski prihvatljivu sol, zaslađivač bez šećera i manje od 0.01 w/V% svih konzervansa pored samog propranolola ili njegove farmaceutski prihvatljive soli.
The solution according to anyone of claims 1 to 3, wherein the propranolol or pharmaceutically acceptable salts thereof is present in an amount of from 0.01 to 5% w/V, for example 0.01 to 1% w/V. 
Vodena otopina sukladno zahtjevu 1, naznačeno time, da je propranolol ili njegova farmaceutski prihvatljiva sol, prisutan u količini od 0.01 do 5% w/V.
The solution according to claim 5, wherein the at least one flavouring agent is selected from any of the cherry, lemon, lime, mandarin, orange, tangerine, mint, strawberry, banana, caramel, liquorice, passion-fruit, peach, raspberry, tutti-frutti, grapefruit, vanilla, cream, chocolate, grape flavour or mixture thereof, for example selected from the vanilla and strawberry flavour, and is present in an amount of from 0 to 5% w/V, e.g. 
Vodena otopina sukladno zahtjevu 3, naznačeno time, što najmanje jedno sredstvo za poboljšanje okusa odabrano od bilo kojeg od slijedećih; višnje, limuna, limete, mandarine, narandže, crvene narandže, mente, jagode, banane, karamele, laktoze, marakuje, breskve, maline, tuti-frutija, grejp, vanilije, slatkog vrhnja, čokolade, grožđa ili njihove mješavine, i prisutna je u količini od 0 do 5% w/V, npr.
The solution according to claim 6, wherein the at least one flavouring agent is vanilla in an amount of from 0.01 to 0.5% w/V. 
Vodena otopina sukladno zahtjevu 4, naznačeno time, što je najmanje jedno sredstvo za poboljšanje okusa vanilija u količini od 0.01 do 0.5% w/V.
The solution according to any one of claims 5 to 7, wherein the at least one viscosity increasing agent is selected from cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose, poloxamers, from gums, guar gum, tragacanthe gum, acacia gum, xanthane gum, gelane gums, alginic derivatives, alginic acid, sodium alginate, polyvinylpyrrolidone, from silicates, bentonite, laponite, veegum, more particularly from non-ionic poloxamers, polyvinylpyrrolidone and cellulose ethers, in an amount of from 0 to 15% w/V, e.g. 
Vodena otopina sukladno zahtjevu 3, naznačeno time, što je najmanje jedan sredstvo za povećanje viskoznosti odabrano između derivata celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, guma, guar gume, tragakant gume, gume akacije ksantan gume, želatinske guma, alginskih derivata, alginske kiseline, natrij alginata, polivinilpirolidona, silikata, bentonita, laponita, veegume, još poželjnije između neionskih poloksamera, polivinilpirolidona i etera celuloze, u količini od 0 do 15% w/V, npr.
The solution according to anyone of claims 1 to 10, wherein the at least one non-sugar type sweetener is selected from saccharin, saccharin salts, sodium saccharin, calcium saccharin, sucralose, potassium acetosulfam, stevioside, steviol, mannitol, erythritol, lactitol, maltitol, alitame, miraculin, monellin, thaumatin, and mixture thereof, and for example selected from saccharin sodium, and is in an amount of from 0.05 to 0.5% w/V. 
Vodena otopina sukladno bilo kojem od zahtjeva 1 do 8, naznačeno time, da je najmanje jedan zaslađivač bez šećera odabran između saharina, soli saharina, natrij saharina, kalcij saharina, saharoze, kalij acetosulfama, steviozida, steviola, manitola, eritritola, laktitola, maltitola, alitama, mirakulina, monelina, taumatina, i njihove mješavine i u količini od 0.05 do 0.5% w/V.
The solution according to claim 6 wherein propranolol is present in an amount of 0.250 to 1% w/V and vanilla is present in an amount of 0.01 to 1% w/V and wherein said aqueous solution does not contain a preservative agent. 
Vodena otopina sukladno zahtjevu 1, naznačeno time, da je propranolol prisutan u količini od 0.250 do 1 % w/V i vanilija je prisutna u količini od 0.01 do 1 % w/V i pri čemu navedena vodena otopina ne sadrži konzervans.
The solution according to anyone of claims 1 to 12, wherein the propranolol or pharmaceutically acceptable salts thereof is propranolol hydrochloride in an amount of 0.428 or 0.57 % w/V wherein the at least one sweetener is saccharin sodium in an amount of 0.15% w/V, wherein the at least one flavouring agent is a mixture of vanilla and strawberry flavour in an amount of 0.32% w/V the at least one viscosity increasing agent is hydroxyethylcellulose in an amount of 0.35 % w/V. 
Pripravak sukladno bilo kojem od zahtjeva 1 do 10, naznačeno time, da je propranolol ili njegova farmaceutski prihvatljiva sol propranolol hidroklorid u količini od 0.428 ili 0.57 % w/V, pri čemu je najmanje jedan zaslađivač saharin natrij u količini od 0.15% w/V, pri čemu je najmanje jedna aroma mješavina arome vanilije i jagode u količini od 0.32% w/V, a najmanje jedno sredstvo za povećanje viskoznosti je hidroksietilceluloza u količini od 0.35 % w/V.
Cy is a monocyclic or bicyclic ring system selected from C3-10cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein each of the said C3-10cycloalkyl, heterocyclyl, aryl and heteroaryl groups is optionally and independently substituted with one, two, or three substituent groups selected from halogen, -C1-3-alkyl, -OC1-3-alkyl, -CF3, cyano, oxo, -N(C1-3-alkyl)2, -NH(C1-3-alkyl), -NHCOC1-3-alkyl, -C(O)C1-3-alkyl, -C(O)OC1-3alkyl, hydroxyC1-3alkyl, or heteroaryl; and 
Spoj, naznačen time, da ima formulu I: u kojoj: Cy je monociklički ili biciklički sustav prstena odabran od sljedećih: C3-10-cikloalkil, heterociklil, aril i heteroaril, pri čemu je svaka od navedenih skupina C3-10-cikloalkila, heterociklila, arila i heteroarila, opcijski i neovisno supstituirana s jednom, dvije ili tri supstituentske skupine odabrane od sljedećih: halogen, -C1-3-alkil, -OC1-3-alkil, -CF3, cijano, okso, -N(C1-3-alkil)2, -NH(C1-3-alkil), -NHCO-C1-3-alkil, -C(O)-C1-3-alkil,
The compound of formula I according to claim 1, wherein: Cy is a phenyl, cyclohexyl, indanyl, 2,3-dihydrobenzofuranyl or tetrahydroquinolinyl group, each optionally substituted with one, two, or three substituent groups independently selected from -Cl, -F, C1-3alkyl, oxo and CN; and 
Spoj formule I prema zahtjevu 1, naznačen time, da: Cy je fenilna, cikloheksilna, indanilna, 2,3-dihidrobenzofuranilna ili tetrahidrokinolinilna skupina, od kojih je svaka opcijski supstituirana s jednom, dvije ili tri supstituentske skupine neovisno odabrane od sljedećih: -Cl, -F, C1-3-alkil, okso i CN; i
The compound of formula I according to claim 1 or 2, wherein: Cy is phenyl optionally substituted with one, two, or three substituent groups independently selected from -Cl, -F, C1-3alkyl and CN. 
Spoj formule I prema zahtjevu 1 ili 2, naznačen time, da: Cy je fenil koji je opcijski supstituiran s jednom, dvije ili tri supstituentske skupine neovisno odabrane od sljedećih: -Cl, -F, C1-3-alkil i CN.
is -CH3. The compound according to claim 1 selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: